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Editorial on the Research Topic
Factors Promoting Development of Fibrosis in Crohn’s Disease
Crohn’s disease is a form of inflammatory bowel disease, which results in areas of chronic inflam-
mation at any point in the gastrointestinal tract. Intestinal fibrosis is a common but debilitating 
complication of Crohn’s disease for which currently there is no medical treatment. In a number 
of cases, significant fibrosis is already present at the time of disease diagnosis (1), and 40–70% of 
Crohn’s disease patients require surgery in the 10 years following diagnosis, with the development 
of fibrotic strictures being the leading indication for surgery in small bowel disease (2). Fibrosis 
occurs due to excessive deposition of extracellular matrix (ECM), particularly fibrous collagen, and 
dysregulated turnover of ECM. Affected tissue becomes hardened and thickened, leading to a loss of 
function. Fibrogenesis in Crohn’s disease is a multifactorial process, influenced by immunological, 
environmental, genetic, and disease-related factors (3–6). It is not currently known how or why 
fibrosis develops in such a high population of patients. Fibrosis follows the path of inflammation 
and has not been seen in areas unaffected by inflammation; however, inflammation is not required 
to propagate fibrosis once it has been initiated (7). This Research Topic brings together experts in the 
field to discuss recent advances in the pathogenesis of fibrosis and future perspectives for detection, 
treatment, and prevention of the condition.
Rogler and Hausmann introduce the topic with a review on the main factors that promote 
development of fibrosis in Crohn’s disease. They discuss new findings that challenge the current 
dogma in this area and highlight the importance of these when developing novel treatment 
strategies. It is clear that we need to expand our horizons when we consider which cells contribute 
to fibrosis and look beyond primary mesenchymal cells. While fibroblasts and smooth muscle 
cells are significant contributors to fibrosis, increasing evidence suggests a role for epithelial and 
endothelial cells via epithelial or endothelial-to-mesenchymal transition (8–10). Cytokines have 
long been known as key players in fibrogenesis, with those produced during the inflammatory 
response, and found at increased levels in the inflamed IBD gut contributing. In particular, 
transforming growth factor-β (TGF-β) and tumor necrosis factor-α (TNF-α) have been exten-
sively studied and both stimulate collagen accumulation and mesenchymal cell activation (11). 
However, these same cytokines are also capable of stimulating both epithelial and endothelial-
to-mesenchymal transition (8, 12) thus their pro-fibrotic effects extend further than originally 
thought.
The role of cytokines in fibrogenesis has been reviewed in depth in this Research Topic by 
Curciarello et al. Cytokines such as TGF-β, IL-1β, TNF-α, and IL-17A can have a direct effect on 
mesenchymal cells, preventing their migration away from the site of fibrogenesis, activating them to 
produce ECM components such as collagen, inducing their proliferation, and stimulating production 
of tissue inhibitors of matrix metalloproteinases, which prevent the normal breakdown of collagen 
2Bailey Fibrosis in Crohn’s Disease
Frontiers in Medicine | www.frontiersin.org September 2017 | Volume 4 | Article 160
(13–16). Cytokines such as IL-13, IL-6, and IL-33 contribute 
to fibrogenesis via an indirect effect on mesenchymal cells; for 
example, they prevent synthesis of MMPs and induce secretion of 
pro-fibrotic cytokines, such as TGF-β, by other cell types which 
are then capable of stimulating collagen deposition (17–20).
There are currently no medical therapies available to treat 
existing fibrosis. While major advances in surgical strategies 
have been made in recent years, such as strictureplasty, these 
procedures are not without risks and many patients prefer to 
avoid surgery. Early detection and intervention are key to mini-
mizing damage but, as previously mentioned, fibrosis develops 
silently, demonstrated by the fact that a number of patients 
will already have significant fibrosis at the time of diagnosis 
(1). The ability to rapidly screen newly diagnosed patients to 
predict which already have fibrosis, or are at significant risk 
of developing fibrosis, could be key to improving outcomes 
for patients in the future. James and Tyrrell-Price discuss a 
recent publication on the accuracy of hybrid positron emission 
tomography (PET)/magnetic resonance-enterography (MR-E) 
and PET/computed tomography-enterography (CT-E) for the 
detection of fibrosis in Crohn’s disease (21). Differentiation 
between fibrotic strictures and inflammatory strictures is vital 
since treatment protocols differ between the two states; inap-
propriate classification could lead to unnecessary surgery or 
futile attempts at medical therapy. This study has evaluated these 
two radiological techniques to determine their effectiveness in 
predicting which patients will respond to medical therapy and 
which require surgical intervention. In this small study, PET/
MR-E showed greater success in accurately detecting fibrosis 
than PET/CT-E; however, while these data are encouraging 
and indicate that PET/MR-E may be a useful diagnostic tool, 
current low availability and high cost prohibit its use as a rou-
tine screening procedure.
Genetic factors are likely to play in a role in the susceptibility 
of an individual to developing fibrotic disease. If these factors can 
be determined, it could unlock new treatment pathways or be 
used to predict the course of disease in newly diagnosed patients. 
Verstockt and Cleynen have reviewed the current knowledge 
of genetic influences on fibrogenesis in Crohn’s disease. Several 
genes have been implicated in the pathogenesis of Crohn’s 
disease; however, very few have been identified as independent 
risk factors for developing fibrostenotic disease. The most stud-
ied genetic predictor for fibrotic disease is nucleotide-binding 
oligomerization domain-containing protein 2 (NOD2). While a 
link has been found between NOD2 and fibrostenotic disease in 
a number of studies (22–26), other groups have been unable to 
find this association (6, 27); therefore, the picture is unclear, and 
NOD2 genotyping in all patients is unjustified at present.
A major challenge for the future will be to develop novel medi-
cal therapies to treat and prevent fibrosis to reduce reliance on 
surgical techniques. Traditionally, fibrosis has been thought of as 
irreversible; however, this may not be the case; fibrosis has been 
shown to be reduced following strictureplasty (28), giving hope 
for new treatment strategies. Excellent progress has been made 
in the field of surgery but continuation of investigation into the 
processes that stimulate fibrogenesis and development of animal 
models with which to trial candidate therapies are critical if we 
are to achieve the holy grail that is medical treatment of fibrosis.
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